Jan 03, 2024
PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference
Apr 07, 2020
PTC Announces Regulatory Update on Risdiplam for Spinal Muscular Atrophy (SMA)
Feb 03, 2020
PTC Therapeutics Announces First Publication of Real-World Data Showing Translarnaä (ataluren) Significantly Preserves Ability to Walk for Longer in Children with Duchenne Muscular Dystrophy
Jan 23, 2020
Risdiplam (RG7916) Pivotal FIREFISH Study Demonstrated Statistically Significant Improvement in Infants with Type 1 Spinal Muscular Atrophy
Nov 11, 2019
Risdiplam (RG7916) Pivotal SUNFISH Study Demonstrates Statistically Significant Improvement for Patients with Type 2/3 Spinal Muscular Atrophy
Oct 24, 2019
PTC Therapeutics Announces Results from Long-Term AADC Deficiency Gene Therapy Treatment Demonstrating Sustained Improvements
Oct 07, 2019
Visiongain Report Looks at Opportunities Within the $257bn Rare Disease Drugs Market
Oct 04, 2019
PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna(TM) (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy
Jun 28, 2019
PTC Provides Update on Translarna(TM) (ataluren) Application for Label Expansion
Jun 07, 2019
PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age
Apr 29, 2019
Translarna(TM) (ataluren) is the First Therapy Approved in Brazil for Duchenne Muscular Dystrophy
Feb 13, 2019
PTC Therapeutics Launches Fifth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy
Jan 31, 2019
PTC Therapeutics Launches New Program to Support Research Projects in Rare, Genetic Disorders
Oct 06, 2018
PTC Therapeutics Announces Initial Data from Patient Registry Demonstrating Translarna(TM) (ataluren) Slows Disease Progression in Children with Duchenne Caused by a Nonsense Mutation
Oct 03, 2018
Risdiplam Demonstrates Preliminary Evidence of Clinical Benefit in Type 1, 2, & 3 Spinal Muscular Atrophy Patients
Sep 07, 2018
PTC Therapeutics Announces Winners of Global Duchenne Muscular Dystrophy Patient Group STRIVE Awards in Recognition of World Duchenne Awareness Day
Aug 24, 2018
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 23, 2018
PTC Therapeutics Successfully Completes Acquisition of Agilis Biotherapeutics
Aug 07, 2018
Global Genes® Announces RARE Champion of Hope Award Recipients to be Honored at RARE Patient Advocacy Summit
Aug 07, 2018
PTC Therapeutics Reports Second Quarter 2018 Financial Results and Provides a Corporate Update